ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.02
+3.07%Sep 3, 2026, 11:00 UTC
Eledon Pharmaceuticals dosed the first patients under compassionate use of tegoprubart in highly sensitized patients with pre-existing antibodies receiving a kidney transplant.
Source:Sep 3, 2026, 11:00 UTC
Eledon Pharmaceuticals enrolled the first patients in a new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant.
Source:Sep 3, 2026, 11:00 UTC
Eledon Pharmaceuticals submitted an Investigational New Drug application to the U.S. FDA for a registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes.
Source:Jun 25, 2026, 11:00 UTC
Natera and Eledon Pharmaceuticals announced a strategic partnership to incorporate Natera's Prospera test into Eledon's planned Phase 3 kidney transplant trial.
Source:Jun 8, 2026, 11:00 UTC
Eledon Pharmaceuticals announced updated results from an investigator-initiated trial of tegoprubart in islet cell transplantation for type 1 diabetes at UChicago Medicine.
Source: